Ranbaxy Laboratories Limited Corporate Filings & Announcements

Latest corporate announcements and filings from Ranbaxy Laboratories Limited on BSE

Search Inside the pdf :

Ranbaxy Laboratories Limited

31 Mar 2015

SAST

Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

BSE India

Sun Pharmaceutical Industries Ltd has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

pdf

Ranbaxy Laboratories Limited

25 Mar 2015

Corp. Action

Fixes Record Date for Scheme of Amalgamation

BSE India

Sun Pharmaceutical Industries Limited has informed BSE that the Committee of the Directors of the Company has March 24, 2015, fixed April 07, 2015 as the record date in order to determine the names of the shareholders of erstwhile Ranbaxy who would be entitled to receive 8 ( eight) equity shares of Re.1 each of the Company for every 10 (ten) equity shares of Rs.5 each of erstwhile Ranbaxy held and to determine the names of the NCD holders who would...

pdf

Ranbaxy Laboratories Limited

24 Mar 2015

Corp. Action

Updates on Scheme of Arrangement

BSE India

Ranbaxy Laboratories Ltd has informed BSE that Sun Pharmaceutical Industries Limited ("Sun Pharma") has on March 23, 2015, received the approval from Reserve Bank of India (RBI) for a) the issue of equity shares of Sun Pharma to the Non Resident holders of equity shares of Ranbaxy Laboratories Limited ("Ranbaxy") and b) transfer of overseas investments held by Ranbaxy in its Joint Venture and Wholly Owned Subsidiaries to Sun Pharma, pursuant to the...

pdf

Ranbaxy Laboratories Limited

17 Mar 2015

SAST

Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

BSE India

Ranbaxy Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

pdf

Ranbaxy Laboratories Limited

16 Mar 2015

SAST

Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

BSE India

Ranbaxy Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

pdf

Ranbaxy Laboratories Limited

09 Mar 2015

Corp. Action

Updates on Scheme of Arrangement

BSE India

Ranbaxy Laboratories Ltd has informed BSE that the Honble High Court of Punjab & Haryana has orally pronounced the Order on March 09, 2015, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories Ltd. with Sun Pharmaceutical Industries Ltd. under Sections 391 to 394, Sections 78 and 100 of the Companies Act. 1956 and Section 52 of the Companies Act, 2013.Certified true copy of the Order is awaited.

Ranbaxy Laboratories Limited

03 Mar 2015

Company Update

Clarification

BSE India

Ranbaxy Laboratories Ltd has clarified with respect to media report titled "Ranbaxy loses drug pleas in US", which appeared in the Financial Express dated March 1, 2015. "Previously, we had informed you on November 21, 2014 that the Company had filed a complaint against the US FDA in D.C. Federal Court and in the first instance asking the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is...

Ranbaxy Laboratories Limited

20 Feb 2015

SAST

Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

BSE India

Ranbaxy Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

pdf

Ranbaxy Laboratories Limited

03 Feb 2015

SAST

Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

BSE India

Ranbaxy Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

pdf

Ranbaxy Laboratories Limited

02 Feb 2015

Company Update

Sun Pharma receives US FTC clearance for Ranbaxy acquisition

BSE India

Ranbaxy Laboratories Ltd has informed BSE regarding a Press Release dated February 02, 2015 titled "Sun Pharma receives US FTC clearance for Ranbaxy acquisition".

pdf

Is Ranbaxy Laboratories Limited worth buying?

5 Votes:

Buy 40.0%

Hold 60.0%